Relative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in comparison to adalimumab in patients with active rheumatoid arthritis

Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial

(2017) Roy Fleischmann et al.   LANCET

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis

(2017) Peter C. Taylor et al.   NEW ENGLAND JOURNAL OF MEDICINE

Comparative efficacy and safety of baricitinib 2 mg and 4 mg in patients with active rheumatoid arthritis

(2017) Y. H. Lee et al.   ZEITSCHRIFT FUR RHEUMATOLOGIE

Uncertainty in Treatment Rankings: Reanalysis of Network Meta-analyses of Randomized Trials

(2016) Ludovic Trinquart et al.   ANNALS OF INTERNAL MEDICINE

Rheumatoid arthritis

(2016) Josef S Smolen et al.   LANCET

Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases

(2016) Robert Roskoski   PHARMACOLOGICAL RESEARCH

Meta-Analysis of Genetic Association Studies

(2015) Young Ho Lee   Annals of Laboratory Medicine

Association of the MTHFR C677T and A1298C polymorphisms with methotrexate toxicity in rheumatoid arthritis: a meta-analysis

(2014) Gwan Gyu Song et al.   CLINICAL RHEUMATOLOGY

The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers

(2014) Jack G. Shi et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Network meta-analysis for comparing treatment effects of multiple interventions: an introduction

(2014) Ferrán Catalá-López et al.   RHEUMATOLOGY INTERNATIONAL

Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials

(2014) Gwan Gyu Song et al.   KOREAN JOURNAL OF INTERNAL MEDICINE

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2013) David Moher   ANNALS OF INTERNAL MEDICINE

Evidence Synthesis for Decision Making 4

(2013) Sofia Dias et al.   MEDICAL DECISION MAKING

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

(2012) Ronald F. van Vollenhoven et al.   NEW ENGLAND JOURNAL OF MEDICINE

Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies

(2012) J. P. T. Higgins et al.   Research Synthesis Methods

Automating network meta-analysis

(2012) Gert van Valkenhoef et al.   Research Synthesis Methods

Associations between interleukin-10 polymorphisms and susceptibility to rheumatoid arthritis: a meta-analysis

(2011) Young Ho Lee et al.   MOLECULAR BIOLOGY REPORTS

Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial

(2010) Georgia Salanti et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis

(2010) Debra M Meyer et al.   Journal of Inflammation-London

Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6

(2010) Jill E. Chrencik et al.   JOURNAL OF MOLECULAR BIOLOGY

The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials

(2010) Young Ho Lee et al.   RHEUMATOLOGY INTERNATIONAL

Janus kinases in immune cell signaling

(2009) Kamran Ghoreschi et al.   IMMUNOLOGICAL REVIEWS

Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations

(2008) D. Aletaha et al.   ARTHRITIS AND RHEUMATISM